New Indication: Avelumab and Axitinib in Thymic Carcinoma
Study
Single-arm, multicentre, phase 2 trial
|
Had received at least one line of platinum-based chemotherapy
|
Advanced stage thymoma or thymic carcinoma
|
Avelumab 10 mg/kg/14 day and axitinib 5 mg x 2. (N:32)
|
Efficacy
ORR: 34% (CR: 0, PR: 34%) and SD: 56%
|
mPFS: 7.5 months
|
DOR: 5.5 month
|
Safety
Grade 1 or 2 infusion reactions: 9%
|
Grade ≥3 AEs: Hypertension:19%, CK increase:9%
|
Deaths due to adverse events: No
|
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022